[1]张帅,贾梦岩,罗裕强,等.透明质酸钠治疗髌骨软化症的疗效:52 周前瞻性临床随访[J].南方医科大学学报,2019,(07):791.[doi:10.12122/j.issn.1673-4254.2019.07.07]
点击复制

透明质酸钠治疗髌骨软化症的疗效:52 周前瞻性临床随访()
分享到:

《南方医科大学学报》[ISSN:1673-4254/CN:44-1627/R]

卷:
期数:
2019年07期
页码:
791
栏目:
出版日期:
2019-07-15

文章信息/Info

Title:
Hyaluronate acid for treatment of chondromalacia patellae: a 52-week follow-up study
作者:
张帅贾梦岩罗裕强王新光史占军肖军
关键词:
髌骨软化症髌股关节炎透明质酸钠透明质酸
Keywords:
chondromalacia patellae patellofemoral arthritis sodium hyaluronate hyaluronic acid
DOI:
10.12122/j.issn.1673-4254.2019.07.07
摘要:
目的观察采用髌骨下入路注射透明质酸钠(HA)治疗髌骨软化症(CP)的临床疗效。方法纳入诊断为CP的患者(n=88), 根据影像学特点进行分组,表现为早期CP的纳入CP组(n=50),具备骨关节炎表现的纳入髌股关节炎组(n=38)。两组均采用髌 骨下给药位点HA注射治疗,每周1次,连续用药5周。评估参数包括首要指标:记录给药前、给药后4、12、26、52周的WOMAC 评分和Lequesne指数;次要指标:给药前、给药后1~4周的步行30 m用时、上下楼梯用时。结果两组的患者在给药后4、12、26、 52周的WOMAC评分及Lequesne指数分别与各自的给药前相比均有显著改善(P<0.01)。两组之间比较,在给药前、给药后4、 12 周的WOMAC评分及Lequesne 指数评分对比未见统计学差异(P>0.05);但是,髌股关节炎组在给药后26 及52 周的 WOMAC评分及Lequesne指数显著高于CP组(P<0.05)。两组的患者在给药后1、2、3、4周的步行30 m用时、上楼梯用时、下楼 梯用时均显著改善(P<0.05);而两组之间比较,未发现显著性差异(P>0.05)。结论采用髌骨下入路关节腔内注射HA治疗CP 疗效显著。HA治疗早期CP的中远期疗效显著优于出现髌股关节炎的晚期CP。
Abstract:
Objective To assess the therapeutic effect of hyaluronate acid (HA) injection through the subpatellar route for treatment of chondromalacia patellae (CP). Methods Eighty-eight patients with the diagnosis of CP were enrolled in this prospective study, including 38 with early CP (CP group) and 50 with advanced CP (patellofemoral arthritis group) diagnosed based on image presentations. All the patients received intra-articular HA injections through a subpatellar route once a week for 5 consecutive weeks. The primary outcome measures included WOMAC index scores and Lequesne scores before and at 4, 12, 26 and 52 weeks after the injections. The secondary outcome measures included the 30-m walking time and stair ascending and descending time (one floor) before and at 1, 2, 3, and 4 weeks after the injections. Results In both groups the patients showed significantly decreased WOMAC scores and Lequesne scores at 4, 12, 26 and 52 weeks after HA injections as compared with the baseline scores (all P<0.01). No significant difference was found between the two groups in WOMAC scores and Lequesne scores at 4 or 12 weeks after the injections (both P>0.05). The WOMAC scores and Lequesne scores at 26 and 52 weeks after the injections were significantly higher in patellofemoral arthritis group than in CP group (both P<0.05). In both groups, the 30-m walking time and the stair ascending and descending time decreased significantly at 1, 2, 3, and 4 weeks after HA injections (all P<0.05) without significant differences between the two groups (all P>0.05). Conclusion HA injection through the subpatellar route is effective for treatment of CP. HA injection produces better long-term efficacy for treatment of early CP than for advanced CP where patellofemoral arthritis occurs.
更新日期/Last Update: 1900-01-01